Compounds that induce degradation of anti-apoptotic bcl-2 family proteins and the uses thereof
US-2019135801-A1 · May 9, 2019 · US
Compositions and methods for inhibiting antiapoptotic Bcl-2 proteins as anti-aging agents
US11331328B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11331328-B2 |
| Application number | US-201515308552-A |
| Country | US |
| Kind code | B2 |
| Filing date | May 5, 2015 |
| Priority date | May 5, 2014 |
| Publication date | May 17, 2022 |
| Grant date | May 17, 2022 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present disclosure provides compositions and methods for selectively killing senescent cells, wherein the selective killing of senescent cells delays aging and treats age-related disorders.
First claim
Opening claim text (preview).
What is claimed is: 1. A method of treating bone marrow injury in a subject who has not been administered cancer therapy, the method comprising contacting cells in the subject's bone marrow with a therapeutically effective amount of a compound that inhibits the biological activity of Bcl-xL and Bcl-2 protein that is present in p16 positive senescent cells in the bone marrow, wherein the compound is selected from GX15-070 (obatoclax), gossypol (AT-101), apogossypolone, TW37, TM-1206, ABT-737, ABT-263 (navitoclax), WHEI539, and combinations thereof, whereby the compound selectively removes the senescent cells in comparison with non-senescent cells in the subject's bone marrow, thereby delaying progression of the injury. 2. The method of claim 1 , wherein the LD 50 of the compound for non-senescent cells is greater than 10 times higher than the LD 50 for the senescent cells. 3. A method of treating bone marrow injury in a subject who does not have cancer, the method comprising contacting cells in the subject's bone marrow with a therapeutically effective amount of a compound, whereby the compound inhibits the biological activity of Bcl xL and Bcl-2 protein and selectively removes the senescent cells in comparison with non-senescent cells in the subject's bone marrow, thereby delaying progression of the injury, wherein the compound is selected from GX15-070 (obatoclax), gossypol (AT-101), apogossypolone, TW37, TM-1206, ABT-737, ABT-263 (navitoclax), WHEI539, and combinations thereof.
Assignees
Inventors
Classifications
- A61K31/5377Primary
not condensed and containing further heterocyclic rings, e.g. timolol · CPC title
General methods for the preparation of peptides {, i.e. processes for the organic chemical preparation of peptides or proteins of any length} · CPC title
- A61K31/635Primary
having a heterocyclic ring, e.g. sulfadiazine · CPC title
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11331328B2 cover?
- The present disclosure provides compositions and methods for selectively killing senescent cells, wherein the selective killing of senescent cells delays aging and treats age-related disorders.
- Who is the assignee on this patent?
- Univ Arkansas, Bioventures Llc
- What technology area does this patent fall under?
- Primary CPC classification A61K31/5377. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue May 17 2022 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 10 related publications on this page (citations in our corpus or others sharing the same primary CPC).